The search session has expired. Please query the service again.
The search session has expired. Please query the service again.
The search session has expired. Please query the service again.
The search session has expired. Please query the service again.
The search session has expired. Please query the service again.
The search session has expired. Please query the service again.
The search session has expired. Please query the service again.
The search session has expired. Please query the service again.
The search session has expired. Please query the service again.
The search session has expired. Please query the service again.
The search session has expired. Please query the service again.
The search session has expired. Please query the service again.
The search session has expired. Please query the service again.
The search session has expired. Please query the service again.
Patients with acute myeloblastic leukemia (AML) are divided according to the French
American British (FAB) classification into eight subgroups (M0 to M7) on the basis of their degree
of maturation/differentiation. However, even if immunophenotypical characterization by flow cytometry
is routinely used to distinguish between AML and acute lymphoblastic leukemia (ALL), it
is not yet well established for the identification within the AML subgroups. Here we show that certain
subgroups of AML can be...
Download Results (CSV)